

knows what "constructive" means these days.

Naomi Sandler

Department of Biochemistry,
Hebrew University of Jerusalem,
91904 Jerusalem, Israel
E-mail: sandler@vms.huji.ac.il

Forman's acerbic but perceptive review of *The Flight from Science and Reason* (1) may cause some readers to suspect that he is a spokesperson for an evil empire—the Academic Left—that is allegedly in control of most branches of scholarship and has orchestrated the onslaught on science. To the degree that this empire has any basis in reality, however, it owes its viability partly to the indifference of the scientific community. An indifference that, until quite recently, manifested itself by the paucity of dialog and debate between scientists and those social scientists who are characterized in Forman's review as "postmodernists, feminists, relativists . . . [and] social constructivists. . . ."

The lack of substantive dialogue was, in my view, a significant enabling factor in the ascendancy of postmodernist ideas about the nature of science during the two decades before 1994. In that year the publication of Gross, Levitt, and Lewis' *Higher Superstition*

(2) initiated such a dialog, and interest in the issues addressed was subsequently reinforced by *The Flight from Science and Reason*.

I applaud the choice of an historian (and one who is competent to address flaws in the book's arguments) as the reviewer, because his remarks constitute a continuation of the healthy dialog between scientists and social scientists. Whether or not one agrees with Forman's assessment of the book, his comments provide a salutary reminder that such books do not mark the end or even the beginning of the end of the "science wars," but merely the end of the beginning (*pace* Churchill).

Charles A. Ziegler

Department of Anthropology,
Brandeis University,
Waltham, MA 02254-9110, USA

References

1. P. R. Gross, N. Levitt, M. W. Lewis, *The Flight from Science and Reason* (Johns Hopkins Univ. Press, Baltimore, MD, 1994).
2. P. R. Gross and N. Levitt, *Higher Superstition* (Johns Hopkins Univ. Press, Baltimore, MD, 1994).

Response: I am sorry that *Science* has chosen not to publish Levitt's letter in full, in the form he kindly communicated it to me. Its readers might then have wondered whether the chief purpose of that letter was to en-

sure that such discussion as Ziegler calls for will not continue to take place in the pages of *Science*. I am, nonetheless, grateful to *Science* for publishing this much of Levitt's letter, for otherwise readers of Trefil's letter would have had no clue that he too writes as one criticized in my review. And I am grateful to Herschbach for making clear to the readers of *Science* that of which Levitt's letter offers no clue, namely, that the volume edited by Gross, Levitt, and Lewis contains more than just Trefil's paper. Although Levitt quotes "in full" my remarks about Trefil, he refrains from quoting in full my sentence containing those remarks.

Paul Forman

Smithsonian Institution,
Washington, DC 20560, USA

Curtailing the AIDS Pandemic

The decision not to go forward with phase III efficacy trials of human immunodeficiency virus type-1 (HIV-1) vaccines in the United States in 1994 (Research News, 17 Dec. 1993, p. 1820) was based in part on the paucity of data suggesting that current vaccine candidates would provide sterilizing immunity, as

What would you say to this statement: "minutes are all it takes to conquer the intricacies of chromatography"? Something like: "Prove it"? Good. The next time you need help with purification, contact Pharmacia Biotech.

Complete purification and separation support

We offer the broadest, most comprehensive range of support to help you get ahead in your research. And to help you stay ahead. Our technical support scientists are always available for you. In fact, every minute of every day people are talking to us about purification and separation. Yearly, we organize detailed purification and separation seminar programs.

You can get a vast amount of technical advice by contacting us. For instance, we can fax a data file to you in minutes—or deliver any of our well-known application handbooks to you. Restated, we're ready to help you anytime and anyway you need it.

Our chromatography products will provide you with speed, consistency, and reliability. Consider, for example, our latest purification systems: ÄKTA™ design (pronounced eckta design). Each system provides you with the digital integration of our more than 50 years of chromatographic expertise with built-in pre-programmed protocols for all major purification methods and techniques. Which means, with Pharmacia Biotech support and products, you can literally conquer chromatography in minutes.

Find out more about Pharmacia Biotech. Give us a call: 1 (800) 526-3593 in the USA; +81 3492 6949 in Japan; +46 18 16 50 11 in Europe and the rest of the world.

Or visit us on the Internet: <http://www.biotech.pharmacia.se>.



Circle No. 28 on Readers' Service Card

well as our poor understanding of the immune correlates of protection. We are arguably not now much closer to having either requirement satisfied. Furthermore, trials of simian immunodeficiency virus (SIV) vaccine candidates have generally been disappointing because, when an immunized macaque is challenged by the virus, it will usually become infected, despite eliciting a range of antiviral immune responses. Three recent findings, however, provide a logical basis for cautiously moving toward phase III trials without satisfying the above requirements.

First, virus load in vaccinated and subsequently SIV-infected macaques, when measured, has consistently been reduced relative to that in unvaccinated controls (1). Second, a strong correlation has been established between low HIV-1 plasma virus load and long-term survival in humans (2). Third, studies of perinatal transmission of HIV-1 (the only form of transmission for which suitable data are available) have shown that low virus load is associated with reduced probability of the virus being transmitted from one individual to another (3). Hence, if HIV-1 vaccines succeed in reducing the virus load in humans for extended periods in subsequent infections, then vaccinees, although they may still get infected,

may have a delayed onset of AIDS. Indeed, preliminary observations of vaccinated, SIV-infected macaques suggest that they may survive longer than unvaccinated, infected macaques (4). Furthermore, the rate of HIV-1 transmission from a vaccinee or an individual with suppressed virus load may be reduced. Such a reduction in infectiousness would slow the rate of spread of the epidemic, with the benefit increasing over time (5).

These considerations suggest a series of crucial experiments to assess the viability of a vaccination program with the goal of reducing infectivity. First, there has been limited follow-up in animal vaccine studies after infection occurs; a long-term benefit in survival should be convincingly demonstrated. Second, couples with just one member who is infected with HIV are a valuable group to study; such cohorts should be expanded to provide the statistical power necessary to determine if there is an association between plasma or genital virus load, or both, and rate of sexual transmission. Third, animal model studies that evaluate transmission rates under natural conditions of exposure could be conducted with virus load and vaccination as variables. Fourth, whether vaccination of humans with the current vaccine candidates leads to dimin-

ished virus load in subsequently infected individuals needs to be carefully evaluated and confirmed.


More than 90% of HIV-1-infected individuals in the world live in developing countries, where they often cannot afford the current batch of highly active antiretroviral drug therapies that can substantially reduce virus load. Thus, a strong argument may be made for going forward with large-scale vaccination programs if the results of the "crucial experiments" listed above are satisfactory (6).

The same line of reasoning suggests that combination drug therapies could mitigate the course of the AIDS epidemic—if these drugs were to be made available worldwide and used appropriately so as to avoid the spread of resistant strains of HIV.

These considerations in no way argue against the pursuit of more effective vaccines than we currently possess. They do argue, however, for more lines of investigation into understanding what might now be achieved.

James I. Mullins

Department of Microbiology and
Department of Medicine,
University of Washington School of Medicine,
Seattle, WA 98195-7740, USA
E-mail: jmullins@uwashington.edu



Produced by
Micropipette Fabrication Instrumentation
from



SUTTER INSTRUMENT COMPANY

40 LEVERONI CT., NOVATO, CA 94949
PHONE: 415-883-0128 FAX: 415-883-0572
EMAIL: INFO@SUTTER.COM WEB: WWW.SUTTER.COM

Circle No. 8 on Readers' Service Card


ISCAN®

EYE MOVEMENT MONITORING SYSTEMS

ISCAN is the world's leading producer of video based eye movement monitoring systems. Our broad range of products set the pace for performance and usability and can be customized to suit any research application.

Products & Features Include:

- * Non-invasive, real-time measurement of pupil position, size and subject's point of gaze.
- * Complete Eye Tracking Laboratories, Benchtop, Head Mounted, High Speed, High Res, Head Tracking, Integrated VR Displays and PC card versions.
- * Data Acquisition Hardware and Analysis Software.



Applications Include:

Fixation Monitoring, Vision Research, Advertising Research, Psycho-Visual Experiments, Vestibular Testing, Reading Studies, Toxicology, Human Factors Evaluation, Cognitive Neuroscience, Drug or Alcohol Response, Aids for the Disabled, Rehabilitation Training, Control in VR Environments.

ISCAN, Inc.
89 Cambridge Street
Burlington, MA 01803
USA

Web: www.iscaninc.com
Email: info@iscaninc.com
Tel: 617-273-4455
Fax: 617-273-0076

Circle No. 10 on Readers' Service Card

References and Notes

1. S. P. Mossman *et al.*, *J. Virol.* **70**, 1953 (1996); S. Lu *et al.*, *ibid.*, p. 3978; Z. R. Israel *et al.*, *ibid.* **68**, 1843 (1994); L. D. Giavedoni *et al.*, *ibid.* **67**, 577 (1993); S. Ahmad *et al.*, *AIDS Res. Hum. Retrovir.* **10**, 195 (1994); C. Bruck *et al.*, *Vaccine* **12**, 1141 (1994).
2. J. W. Mellors *et al.*, *Science* **272**, 1167 (1996).
3. R. E. Dickover *et al.*, *J. Am. Med. Assoc.* **275** (no. 8), 599 (1996); B. Weiser *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, **91**, 8037 (1994); Y. Cao *et al.*, *Nature Med.* **3**, 549 (1997); W. T. Shearer *et al.*, *N. Engl. J. Med.* **336**, 1337 (1997).
4. V. M. Hirsch *et al.*, *J. Virol.* **70**, 3741 (1996).
5. I. M. Longini Jr., S. Datta, M. E. Halloran, *J. Acquired Immune Defic. Syndr. Hum. Retrovir.* **13**, 440 (1996); J. S. Koopman and R. J. Little, *Am. J. Epidemiol.* **142**, 1113 (1995).
6. As with all HIV vaccine programs under consideration, the potential mitigating impact of prolonged infection as well as enhanced risk-taking behaviors in vaccine-treated, at-risk populations must be seriously investigated and weighed.

Cosmic Age

In his Perspective "Cosmic age controversy is overstated" (16 May, p. 1089), Eric J. Chaisson eloquently presents the recent trend estimating the age of the universe to be about 12 billion years. He also indicates that this age is consistent with an open universe.

Using the average value of the Hubble constant measured by Allan Sandage *et al.* (1), $H_0 = 57 \pm 4$ kilometers per second per megaparsec, the age, $t = H_0^{-1}$, is 17 billion years for an open universe, and $t = 2/3 H_0^{-1}$ is 11.5 billion years for an universe having a critical density. Therefore, the encouraging recent developments firming up the age of the universe to be about 12 billion years are in fact more consistent with the favorite inflationary model of the cosmologists.

M. L. Bhaumik
Cosmogenics, 2085 Deer Run,
Los Angeles, CA 90049, USA
E-mail: mlbhaumik@earthlink.net

References

1. A. Sandage *et al.*, *Astrophysics J.* **460**, L15 (1996).

Response: It is generally believed that a universe having a critical density is still "open." Such a universe, indeed favored by cosmic inflation, recedes forevermore—mathematically reaching infinity with a zero velocity. That Bhaumik prefers an age for such a critical-density universe of 11.5 billion years, in contrast to my suggested 12 billion years, is no cause for alarm. In cosmology, 11.5 equals 12.

Eric J. Chaisson
Wright Center for Science Education,
Tufts University,
Medford, MA 02155, USA
E-mail: echaisso@emerald.tufts.edu

ETS1-DNA Binding and Intercalation: Correction

In the article "Intercalation, DNA kinking, and the control of transcription" (9 Feb. 1996, p. 778), we reviewed the hypothesis that minor groove intercalation and DNA kinking represented an important mechanism for the control of transcription (1). This hypothesis was based on a number of examples of protein-DNA complexes available at the time where this mode of interaction was seen to occur: these comprised complexes of the TATA binding protein (2), the HMG-1/2 box proteins SRY (3) and LEF (4), the PurR repressor (5), and ETS1 (6). Subsequently, we discovered (7) that the original structure of the ETS1-DNA complex (6) was in error and that binding of ETS1 to DNA is similar to that of the related transcription factor Pu.1 (8) and does not involve intercalation (7). Thus, discussions pertaining to the ETS1-DNA complex in our article (1) are in error. The other aspects of the article (1) are correct, and the conclusions of the article remain unchanged.

Milton H. Werner
Rockefeller University,
1230 York Avenue,
New York, NY 10021, USA
Angela M. Gronenborn
G. Marius Clore
Laboratory of Chemical Physics,
National Institute of Diabetes and Digestive
and Kidney Diseases,
National Institutes of Health,
Bethesda, MD 20892-0520, USA

References

1. M. H. Werner, A. M. Gronenborn, G. M. Clore, *Science* **271**, 778 (1996).
2. J. L. Kim, D. B. Nikolov, S. K. Burley, *Nature* **365**, 520 (1993); Y. Kim, J. H. Geiger, S. Hahn, P. B. Sigler, *ibid.*, p. 512.
3. M. W. Werner, J. R. Huth, A. M. Gronenborn, G. M. Clore, *Cell* **81**, 705 (1995).
4. J. J. Love *et al.*, *Nature* **376**, 791 (1995).
5. M. A. Schumacher, K. Y. Choi, H. Zalkin, R. G. Brennan, *Science* **266**, 763 (1994).
6. M. H. Werner *et al.*, *Cell* **83**, 761 (1995).
7. M. H. Werner *et al.*, *ibid.* **87** (1996); M. H. Werner *et al.*, *J. Biomol. Nucl. Magn. Reson.*, in press.
8. R. Kodanpani *et al.*, *Nature* **380**, 456 (1996).

Corrections and Clarifications

In the article "New clues to asthma therapies" by Gretchen Vogel (Research News, 13 June, p. 1643), Stephen Holgate's first name was misspelled (p. 1644).

The credit for the photograph at the top of page 1637 in the article "When a habitat is not a home" (News & Comment, 13 June, p. 1636) should have read, "Sandy Desimone/National Audubon Society."

In the News & Comment article "Hughes network expands by a big leap" by Eliot Marshall (23 May p. 1189), it is stated incorrectly that Simon John is the youngest Howard Hughes Medical Institute investigator.


In the report "Large molecular third-order optical nonlinearities in polarized carotenoids" by S. R. Marder *et al.* (23 May, p. 1233), the first names of several co-authors were incorrect. They should have read, Mireille Blanchard-Desce, Sandra Gilmour, Gerold U. Bublitz, and Steven G. Boxer.

In the Table of Contents for the issue of 9 May (p. 914), the name of the author of the Perspective "Are we seeing global warming?" (p. 914), K. Hasselmann, was misspelled.

Letters to the Editor

Letters may be submitted by e-mail (at science_letters@aaas.org), fax (202-789-4669), or regular mail (*Science*, 1200 New York Avenue, NW, Washington, DC 20005, USA). Letters are not routinely acknowledged. Full addresses, signatures, and daytime phone numbers should be included. Letters should be brief (300 words or less) and may be edited for reasons of clarity or space. They may appear in print and/or on the World Wide Web. Letter writers are not consulted before publication.

MORE affordable ICCD cameras!



Just over a year ago, PTI introduced the world's first affordable intensified CCD camera. Now you have a choice of affordable ICCD cameras! Introducing the new IC-200 Gen-2 and IC-300 Gen-3.

NEW IC-200

Gen-2 Intensified CCD Camera
50% higher resolution and gain
compared to the IC-100

\$7995*

NEW IC-300

Gen-3 Intensified CCD Camera
50% higher resolution and
twice the gain of the IC-200

\$9995*



**Photon
Technology
International**

1 Deerpark Drive, Suite F
Monmouth Junction, NJ 08852
(908) 329-0910 Fax 329-9069
Makers of fluorescence research
instruments. Offices worldwide.
For more info, visit our website:
<http://www.pti-nj.com>

*Introductory prices valid in North America only.